As of Thursday, Jan. 26, 2023, the Federal Drug Administration (FDA) has withdrawn Emergency Use Authorization (EUA) for tixagevimab/cilgavimab (EVUSHELD®) secondary to reduced susceptibility to currently circulating COVID-19 variants. HealthLEARN MORE
A summary of the literature to date on Paxlovid, by Stephanie Schneck, PharmD, system clinical pharmacy director Please follow this link below to read the overview on NIRMATRELVIR/RITONAVIR, including theLEARN MORE
Injectable promethazine is considered a high-risk medication that can contribute to serious tissue injury and amputation if extravasation occurs. The removal of injectable promethazine from hospital formularies has been anLEARN MORE
Albumin 5% 250mL and 500mL presentations are critically short secondary to manufacturing delays. The duration of the shortage is unknown and earliest estimates on resolution are mid-late October 2022. HonorHealthLEARN MORE
